US SEC Trading Suspension Halt Orders — July 27, 2026

Nasdaq deficiency for both MVLS (<$50M) and MVPHS (<$15M) for 30 consecutive days—no insider buying or capital allocation actions to defend the stock

Failed to regain $1.00 minimum bid price by July 20, 2026 deadline; also lacks $5M stockholders' equity, making a second compliance period impossible

NYSE American accepted compliance plan but equity deteriorated from $3.8M (Dec 2025) to a $(1.4)M deficit (Mar 2026)—a $5.2M QoQ swing

Trading suspension scheduled for August 4, 2026, unless appeal succeeds—immediate catalyst for price volatility

Losses in 3 of last 4 fiscal years with no forward guidance or insider buying to signal turnaround confidence

No mention of reverse stock split, capital raise, or insider purchases to address compliance—passive stance

Hearing request stays suspension but no assurance of continued listing; appeal process adds uncertainty [NEUTRAL/BEARISH]

Compliance plan acceptance provides an 18-month runway but requires quarterly milestones—high execution risk

Trading to be suspended at open on August 4, 2026—7 days from now—unless hearing panel grants relief

Fails both MVLS ($50M) and MVPHS ($15M) rules simultaneously, making compliance harder

Stockholders' equity swung from positive $3.8M to negative $(1.4)M in one quarter—a 137% QoQ decline

Fails $5M minimum stockholders' equity requirement, eliminating the standard second compliance period

No disclosed capital allocation (no buybacks, no reverse split, no insider buying) to address the 30-day non-compliance

Losses in 3 of 4 most recent fiscal years with no forward guidance or revenue growth data provided

Hearing panel decision is discretionary; no guarantee of continued listing even with appeal

Zero insider purchases or sales reported across all filings—insiders are not signaling confidence

Maximum 18 months from May 2026 to regain compliance; failure means certain delisting

Hearing request creates a binary event—if panel grants extension, stock could rally from distressed levels; if denied, suspension triggers

NYSE acceptance provides a structured path; if company hits quarterly targets, sentiment could improve from current negative

Has until January 19, 2027 to regain compliance; any positive catalyst (e.g., reverse split, capital raise) could trigger a compliance rally

With suspension imminent, short interest may be elevated; a successful appeal could trigger a squeeze

Unlike Nexalin, PMI has no trading halt—provides time for restructuring or M&A to address equity deficit

MVLS closed below $50M for 30 days; if company executes a catalyst (e.g., business update, reverse split), a 10-day compliance rally could restore listing

3 companies received delisting or suspension notices within 3 days (July 22-24, 2026), indicating a potential regulatory crackdown on non-compliant small caps

Picard Medical's $5.2M QoQ equity swing and Nexalin's failure to meet $5M equity threshold suggest a broader trend of cash burn and capital erosion among micro-caps

Zero insider buying across all three filings despite existential threats—management teams are not backing their own stocks

No dividends, buybacks, or M&A disclosed in any filing—companies are in survival mode, not growth mode

All three filings carry negative sentiment with materiality scores of 8-9/10, suggesting no near-term positive catalysts across the cohort

Trading suspension scheduled for August 4, 2026—watch for hearing panel decision before that date for potential stay or denial

180-day compliance deadline is January 19, 2027—monitor for any 8-K filings regarding reverse split, capital raise, or insider buying

NYSE American quarterly compliance reviews—next review likely in Q3 2026; watch for progress on equity restoration

Appeal hearing date—no date set yet, but any announcement will be a key volatility catalyst

10 consecutive business day closing price test for MVLS/MVPHS—any filing showing compliance would be a positive catalyst

Press release on July 27, 2026 announced compliance plan acceptance—watch for subsequent operational updates or equity raises

Watch for insider trading filings (Form 4) in the next 30 days—any insider buying would be a rare bullish signal